Articles on Longevity Economics, Investments, and Science on Life Span Extension
Interviews with researchers, founders, and policymakers, written for readers who are curious, not credentialed.
Will the Longevity Industry Create Hyperscaler-type Healthcare Companies?
Eli Lilly comes to our mind as the first one with its GLP-1 medicine and more preventive medicines in its pipeline. Other large companies like Novo Nordisk, Roche, Pfizer, Johnson & Johnson, Merck, AstraZeneca, and AbbVie are working on preventive medicines.
Will the Emergence of the Longevity Industry Disrupt Today’s Disease-Driven Healthcare System?
The global healthcare system primarily focuses on treating diseases. The emergence of the longevity industry signals a shift toward prevention, health optimization, and extending both lifespan and healthspan.
From Hospitals to Longevity Clinics: Preventive Medicine as a New Business Model
Globally, healthcare has primarily followed a reactive model, with patients seeking care only after symptoms arise or conditions worsen. Hospitals and traditional clinics have generated revenue by diagnosing and treating illnesses.
Emerging Longevity Trend: Preventive Medicine and Therapeutics Have Created a Premium Consumer Market
Recently, preventive and longevity care has emerged as a premium consumer product, atop those advances, among wealthy individuals who spend significant amounts on anti-aging treatments, personalized health monitoring, and longevity-focused medical services.
The Economics of Human Lifespan and Healthspan Extension: Emerging Business Models in Preventive Care and Longevity Industry
Many companies, including longevity clinics, now prioritize healthspan as well as lifespan. Advances in biotechnology, artificial intelligence, genetics, and preventive medicine are creating new business opportunities across healthcare, technology, finance, and consumer wellness.
The Longevity Economy: Why Living Longer Is Creating a Trillion-Dollar Market
The longevity economy has surpassed $600 billion and could hit $2 trillion this decade, here's what's driving the market and who's investing.
Frequently Asked Questions
-
All articles are written by Rajnandini Mohapatra, an independent researcher and writer specializing in the longevity economy, aging science, biotechnology, healthcare innovation, public policy, economics, and investment trends.
-
The blog examines how longevity, science, economics, finance, technology, healthcare, entrepreneurship, and public policy intersect. Content features research-based articles, expert interviews, industry analysis, and commentary on trends shaping longer, healthier lives.
-
Interview guests are chosen for their expertise, achievements, and contributions in longevity-related fields such as aging research, biotechnology, healthcare, investing, entrepreneurship, policy, and innovation.
-
Interviews are typically conducted via email, video calls, or written questionnaires. Discussions address insights, opportunities, challenges, and the future of longevity-related industries and research.
-
Yes. Articles draw on publicly available research, industry reports, academic publications, expert insights, and independent analysis. Sources are cited when appropriate.
-
New articles, interviews, and resources are published regularly as developments arise in longevity science, healthcare, economics, finance, and related fields.
-
No. The content is for educational and informational purposes only and should not be considered medical, financial, legal, or investment advice. Readers should consult qualified professionals before making healthcare or financial decisions.
-
Yes. Reader suggestions are welcome. Please use the Contact page to recommend topics, research areas, or potential interview guests.
-
Yes. Researchers, entrepreneurs, investors, policymakers, and industry leaders interested in contributing are encouraged to reach out through the Contact page.
-
Subscribe by entering your email address in the newsletter signup form. Subscribers receive updates on new articles, interviews, and major developments in the longevity ecosystem.
-
Currently, guest contributions are reviewed on a case-by-case basis. Please contact us with a brief proposal if you are interested in contributing.
-
In addition to subscribing to the newsletter, follow the blog's social media channels to stay connected and receive the latest articles, interviews, and industry insights.